Llwytho...
Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects
Treatment options have significantly expanded in recent years for men with metastatic castration-resistant prostate cancer (mCRPC), with the routine use of immunotherapy (sipuleucel-T) and novel hormonal agents such as enzalutamide and abiraterone acetate prior to taxane-based chemotherapy or radium...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Urol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4707420/ https://ncbi.nlm.nih.gov/pubmed/26834836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215603558 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|